GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021PRNewsWire • 09/15/21
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling StudiesPRNewsWire • 09/13/21
GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform TechnologiesPRNewsWire • 09/09/21
GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical OfficerPRNewsWire • 08/23/21
GT Biopharma, Inc. (GTBP) CEO Tony Cataldo on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21